NCT03776487View on ClinicalTrials.gov

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Clinical Stage 0 Gastric Cancer AJCC v8Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage I Gastric Cancer AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Gastric Cancer AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Gastric AdenocarcinomaLocalized Gastric CarcinomaLocalized Gastroesophageal Junction AdenocarcinomaPathologic Stage 0 Gastric Cancer AJCC v8Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage I Gastric Cancer AJCC v8Pathologic Stage IA Gastric Cancer AJCC v8Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IB Gastric Cancer AJCC v8Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Gastric Cancer AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Gastric Cancer AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Gastric Cancer AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
DRUG

Fluorouracil

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Oxaliplatin

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo partial or total gastrectomy and lymphadenectomy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03776487 - Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | Biotech Hunter | Biotech Hunter